-transparent.png){kind=logo}
While 25 compounds have been formally licensed for the treatment of HIV infection (AIDS), only seven licensed products are currently available for the treatment of chronic hepatitis B virus (HBV) infection: interferon-α, pegylated interferon-α, lamivudine, adefovir (dipivoxil), entecavir, telbivudine and tenofovir (disoproxil fumarate). In contrast to the treatment of HIV infections where the individual drugs are routinely used in combination, for the treatment of chronic HBV infection the individual drugs are generally used in monotherapy. In principle, combination drug therapy should allow reducing the likelihood of drug-resistant development.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Erik De Clercq, and
Geoffrey Férir, and
Suzanne Kaptein, and
Johan Neyts
December 1984,
Journal of the Royal Society of Medicine,
Erik De Clercq, and
Geoffrey Férir, and
Suzanne Kaptein, and
Johan Neyts
January 1989,
Yonsei medical journal,
Erik De Clercq, and
Geoffrey Férir, and
Suzanne Kaptein, and
Johan Neyts
September 1999,
Nederlands tijdschrift voor geneeskunde,
Erik De Clercq, and
Geoffrey Férir, and
Suzanne Kaptein, and
Johan Neyts
February 2000,
Gastroenterology,
Erik De Clercq, and
Geoffrey Férir, and
Suzanne Kaptein, and
Johan Neyts
February 2015,
Hepatology (Baltimore, Md.),
Erik De Clercq, and
Geoffrey Férir, and
Suzanne Kaptein, and
Johan Neyts
April 1986,
British medical journal (Clinical research ed.),
Erik De Clercq, and
Geoffrey Férir, and
Suzanne Kaptein, and
Johan Neyts
October 1986,
British medical journal (Clinical research ed.),
Erik De Clercq, and
Geoffrey Férir, and
Suzanne Kaptein, and
Johan Neyts
April 1980,
Minerva medica,
Erik De Clercq, and
Geoffrey Férir, and
Suzanne Kaptein, and
Johan Neyts
November 2006,
Medizinische Monatsschrift fur Pharmazeuten,
Erik De Clercq, and
Geoffrey Férir, and
Suzanne Kaptein, and
Johan Neyts
January 1992,
Archives of virology. Supplementum,
